Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2,364.10% | -104.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 699.00% | -87.00% | |||
| Operating Income | -699.00% | 87.00% | |||
| Income Before Tax | -118.95% | 129.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -118.95% | 129.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -118.95% | 129.97% | |||
| EBIT | -699.00% | 87.00% | |||
| EBITDA | -775.83% | 88.08% | |||
| EPS Basic | -119.75% | 135.84% | |||
| Normalized Basic EPS | 10.67% | -151.44% | |||
| EPS Diluted | -119.75% | 135.84% | |||
| Normalized Diluted EPS | 10.67% | -151.44% | |||
| Average Basic Shares Outstanding | -4.06% | -2.49% | |||
| Average Diluted Shares Outstanding | -4.06% | -2.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||